Grail Inc
NASDAQ:GRAL
Relative Value
The Relative Value of one
GRAL
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 100.88 USD,
Grail Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
GRAL Competitors Multiples
Grail Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Grail Inc
NASDAQ:GRAL
|
3.7B USD | 25.7 | -9 | -8 | -5.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
389.4B USD | 6.5 | 165.9 | 16.1 | 22.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197B USD | 5.4 | 25.5 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
193.8B USD | 6.7 | 23.9 | 16.3 | 16.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.6B USD | 10 | 31.8 | 23.3 | 24.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.4B USD | 5.7 | 18.2 | 13.7 | 15.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
78B AUD | 3.5 | 18.1 | 12.3 | 15.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43B EUR | 14.2 | 33.4 | 56.9 | 58.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |